Compare Linde PLC (LIN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Repligen Corporation Common Stock — how do they compare? Linde PLC trades at $496.13 (market cap $226.85B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Linde PLC is far larger — about 20.4× Repligen Corporation Common Stock's market cap, and Linde PLC pays a 1.3% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 89 Days and Repligen Corporation Common Stock for 0 Days on average.
| LIN | RGEN | |
|---|---|---|
Market Cap | $226.85B | $11.14B |
Volume | 1,386,042 | 1,259,263 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $194.57 |
52-Week Low | $389.38 | $102.87 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $249.97B | $11.02B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $487.35, up 0.75% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 20.43% net margins, and robust cash flow generation. Analyst consensus is overwhelmingly bullish with a $558.91 price target, representing 15% upside potential. Recent Q2 2026 results exceeded expectations with $4.50 EPS, driven by volume and pricing growth across key markets including electronics.
LIN offers quality exposure to industrial gases with AI chip contract potential, though elevated P/E of 31.75 requires sustained growth. Risks include margin pressure from higher CAPEX and sector-wide competition. The stock presents a compelling opportunity for investors seeking stable industrial exposure with growth catalysts, supported by strong institutional backing and consistent dividend payments.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
